Differential regulation of estrogen receptor alpha turnover and transactivation by Mdm2 and stress-inducing agents.
暂无分享,去创建一个
N. Boulle | S. Daujat | H. Neel | V. Cavaillès | V. Duong | S. Bonnet | J. Chauvet
[1] R. Métivier,et al. Differential Regulation of Estrogen-Inducible Proteolysis and Transcription by the Estrogen Receptor α N Terminus , 2005, Molecular and Cellular Biology.
[2] S. Kato,et al. Ligand‐dependent switching of ubiquitin–proteasome pathways for estrogen receptor , 2004, The EMBO journal.
[3] M. Protopopova,et al. Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors , 2004, Nature Medicine.
[4] W. Shao,et al. Coactivator AIB1 links estrogen receptor transcriptional activity and stability. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[5] Bohdan Wasylyk,et al. Physiological and Pathological Consequences of the Interactions of the p53 Tumor Suppressor with the Glucocorticoid, Androgen, and Estrogen Receptors , 2004, Annals of the New York Academy of Sciences.
[6] C. Glass,et al. A Corepressor/Coactivator Exchange Complex Required for Transcriptional Activation by Nuclear Receptors and Other Regulated Transcription Factors , 2004, Cell.
[7] Timothy M. Errington,et al. Extracellular Signal-Regulated Kinase 7, a Regulator of Hormone-Dependent Estrogen Receptor Destruction , 2003, Molecular and Cellular Biology.
[8] E. Alarid,et al. Thyroid hormone is an inhibitor of estrogen-induced degradation of estrogen receptor-alpha protein: estrogen-dependent proteolysis is not essential for receptor transactivation function in the pituitary. , 2003, Endocrinology.
[9] H. Kinyamu,et al. Estrogen Receptor-Dependent Proteasomal Degradation of the Glucocorticoid Receptor Is Coupled to an Increase in Mdm2 Protein Expression , 2003, Molecular and Cellular Biology.
[10] Z. Nawaz,et al. Specific ubiquitin-conjugating enzymes promote degradation of specific nuclear receptor coactivators. , 2003, Molecular endocrinology.
[11] Kenneth P Nephew,et al. The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-alpha and essential for the antiproliferative activity of ICI 182,780 in ERalpha-positive breast cancer cells. , 2003, Molecular endocrinology.
[12] M. Oren,et al. The p53-Mdm2 module and the ubiquitin system. , 2003, Seminars in cancer biology.
[13] K. Belguise,et al. Receptor-interacting protein 140 binds c-Jun and inhibits estradiol-induced activator protein-1 activity by reversing glucocorticoid receptor-interacting protein 1 effect. , 2003, Molecular endocrinology.
[14] Chawnshang Chang,et al. Phosphorylation‐dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase , 2002, The EMBO journal.
[15] P. Chambon,et al. Phosphorylation by p38MAPK and recruitment of SUG‐1 are required for RA‐induced RARγ degradation and transactivation , 2002, The EMBO journal.
[16] D. Meek. p53 Induction: Phosphorylation Sites Cooperate in Regulating Interatction , 2002, Cancer biology & therapy.
[17] D. McDonnell,et al. The Human Estrogen Receptor-α Is a Ubiquitinated Protein Whose Stability Is Affected Differentially by Agonists, Antagonists, and Selective Estrogen Receptor Modulators* , 2001, The Journal of Biological Chemistry.
[18] B. Wasylyk,et al. Ligand-dependent interaction of the glucocorticoid receptor with p53 enhances their degradation by Hdm2. , 2001, Genes & development.
[19] T. Ishizuka,et al. Human immunodeficiency virus type 1 Tat binding protein-1 is a transcriptional coactivator specific for TR. , 2001, Molecular endocrinology.
[20] J. Nicolas,et al. Reporter cell lines are useful tools for monitoring biological activity of nuclear receptor ligands. , 2001, Luminescence : the journal of biological and chemical luminescence.
[21] J. Thomsen,et al. Mechanisms of estrogen action. , 2001, Physiological reviews.
[22] D. Chalbos,et al. Unliganded and liganded estrogen receptors protect against cancer invasion via different mechanisms. , 2000, Molecular endocrinology.
[23] Pierre Roux,et al. Extinction of Rac1 and Cdc42Hs signalling defines a novel p53-dependent apoptotic pathway , 2000, Oncogene.
[24] G. Liu,et al. Estrogen receptor protects p53 from deactivation by human double minute-2. , 2000, Cancer research.
[25] R. Honda,et al. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase , 2000, Oncogene.
[26] C. Lange,et al. Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[27] Han-Jong Kim,et al. Steroid receptor coactivator-1 and its family members differentially regulate transactivation by the tumor suppressor protein p53. , 1999, Molecular endocrinology.
[28] E. Alarid,et al. Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation. , 1999, Molecular endocrinology.
[29] J. Nicolas,et al. Reporter cell lines to study the estrogenic effects of xenoestrogens. , 1999, The Science of the total environment.
[30] G. Leclercq,et al. Implication of proteasome in estrogen receptor degradation , 1999, FEBS letters.
[31] B. O’Malley,et al. Proteasome-dependent degradation of the human estrogen receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[32] M. Tsai,et al. The Angelman Syndrome-Associated Protein, E6-AP, Is a Coactivator for the Nuclear Hormone Receptor Superfamily , 1999, Molecular and Cellular Biology.
[33] P. Meltzer,et al. In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[34] J. Niland,et al. The MDM2 gene amplification database. , 1998, Nucleic acids research.
[35] Hirofumi Tanaka,et al. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53 , 1997, FEBS letters.
[36] M. Oren,et al. Mdm2 promotes the rapid degradation of p53 , 1997, Nature.
[37] K. McMasters,et al. mdm2 deletion does not alter growth characteristics of p53-deficient embryo fibroblasts. , 1996, Oncogene.
[38] M. Imhof,et al. Yeast RSP5 and its human homolog hRPF1 potentiate hormone-dependent activation of transcription by human progesterone and glucocorticoid receptors , 1996, Molecular and cellular biology.
[39] Guillermina Lozano,et al. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 , 1995, Nature.
[40] D. Moore,et al. Interaction of thyroid-hormone receptor with a conserved transcriptional mediator , 1995, Nature.
[41] M. Parker,et al. Interaction of proteins with transcriptionally active estrogen receptors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[42] D. Weil,et al. In vivo cooperation between introns during pre-mRNA processing. , 1993, Genes & development.
[43] M. Parker,et al. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[44] M. Ptashne,et al. A vector for expressing GAL4(1-147) fusions in mammalian cells. , 1989, Nucleic acids research.
[45] E. Jensen,et al. Oestrogen-receptor interaction in target tissues. , 1969, Biochemical Journal.
[46] B. Katzenellenbogen,et al. ERalpha and ERbeta expression and transcriptional activity are differentially regulated by HDAC inhibitors. , 2006, Oncogene.
[47] H. Richard-Foy,et al. CSN5/Jab1 is involved in ligand-dependent degradation of estrogen receptor {alpha} by the proteasome. , 2005, Molecular and cellular biology.
[48] K. Nephew,et al. Inhibiting proteasomal proteolysis sustains estrogen receptor-alpha activation. , 2004, Molecular endocrinology.
[49] S. Khochbin,et al. Multiple domains of the Receptor-Interacting Protein 140 contribute to transcription inhibition. , 2004, Nucleic acids research.
[50] S. Angeloni,et al. Regulation of estrogen receptor- expression by the tumor suppressor gene p53 in MCF-7 cells , 2004 .
[51] Angélique Gougelet,et al. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells. , 2003, Molecular endocrinology.
[52] B. O’Malley,et al. FRAP reveals that mobility of oestrogen receptor-alpha is ligand- and proteasome-dependent. , 2001, Nature cell biology.
[53] S. Saji,et al. MDM2 enhances the function of estrogen receptor alpha in human breast cancer cells. , 2001, Biochemical and biophysical research communications.
[54] B. O’Malley,et al. The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation. , 2000, Molecular cell.
[55] J. Xu,et al. Nuclear receptor coactivators: multiple enzymes, multiple complexes, multiple functions. , 1999, Journal of Steroid Biochemistry and Molecular Biology.